BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced four presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from April 9-14th, 2021.
| FRAMINGHAM, Mass., April 14, 2021 /PRNewswire/ -- BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced four presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from April 9-14th, 2021.
“BERG has continued to advance our research through multidisciplinary collaborations to impact diagnostic and therapeutic development,” said Dr. Niven R. Narain, BERG Co-founder, President and Chief Executive Officer. “BERG’s platforms, such as BPM 31510 and BPM 42522, are creating valuable assets to help patients during these uncertain times in the areas of breast cancer decision-making, leading protein degradation drug development and skin cancers.” These presentations demonstrate BERG’s ongoing partnerships with leading institutions, such as Walter Reed National Medical Center, Uniformed Services University, Memorial Sloan Kettering Cancer, University of Massachusetts and University of Oxford. “The data presented on breast cancer biomarkers is a testament to the deepening relationship between BERG and DoD,” added Major General Elder Granger, M.D., US Army Retired and Board Director of BERG. “Patients and physicians need to be armed with tools that allow for more specificity of diagnoses and precision in treatment and our work here is making that all possible.” Presentation Details at the AACR Virtual Meeting:
Full abstracts of the posters are available on the AACR website (www.aacr.org). About BERG BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology®, to map disease and revolutionize treatments across oncology, neurology and rare diseases. By taking a Back to Biology™ approach, BERG is able to identify critical biomarkers that can accelerate the discovery and development of treatments aimed at the most promising therapeutic targets and pathways. BERG has leveraged both Interrogative Biology® and traditional R&D methods to develop a robust pipeline of first-in-class product candidates and diagnostics that advance bold innovations that have the potential to improve patient lives. To learn more about how we’re enabling bold innovation, visit berghealth.com. For additional information, please visit http://www.berghealth.com. Media Contact:
SOURCE BERG Health |
View original content to download multimedia:
